Wang Xiu-Ping, Yang Lin-Dong, Zhou Jin-Fang
Department of Paediatrics, Yan'an People's Hospital, Yanan, China.
Medicine (Baltimore). 2018 Jul;97(30):e11557. doi: 10.1097/MD.0000000000011557.
This study investigated the effectiveness and safety of montelukast combined budesonide (MCB) treatment for children with chronic cough-variant asthma (CCVA).In total, 82 cases of children with CCVA, aged 4 to 11 years were included in this study. All cases received either MCB or budesonide alone between May 2015 and April 2017. The primary outcome was lung function, measured by the peak expiratory flow rates (PEFRs) and forced expiratory volume in 1 second (FEV1). The secondary outcome was measured by the clinical assessment score. Furthermore, adverse events (AEs) were also recorded in this study. All outcomes were measured after 8-week treatment.After 8-week treatment, MCB showed greater effectiveness than did budesonide alone in improving the lung function, measured by PEFR V1 (P = .02), and FEV1 (P < .01). Similarly, the clinical assessment score also demonstrated significant difference between the 2 groups (P < .05). In addition, no serious AEs occurred in both groups.The results of this study demonstrate that the effectiveness of MCB is superior to budesonide alone in the treatment of children with CCVA.
本研究探讨了孟鲁司特联合布地奈德（MCB）治疗儿童慢性咳嗽变异性哮喘（CCVA）的有效性和安全性。本研究共纳入82例4至11岁的CCVA儿童。2015年5月至2017年4月期间，所有病例均接受了MCB或单独使用布地奈德治疗。主要结局指标为肺功能，通过呼气峰值流速（PEFRs）和1秒用力呼气容积（FEV1）进行测量。次要结局指标通过临床评估评分进行测量。此外，本研究还记录了不良事件（AEs）。所有结局指标均在治疗8周后进行测量。治疗8周后，在通过PEFR V1（P = 0.02）和FEV1（P < 0.01）测量的肺功能改善方面，MCB显示出比单独使用布地奈德更高的有效性。同样，两组之间的临床评估评分也存在显著差异（P < 0.05）。此外，两组均未发生严重不良事件。本研究结果表明，在治疗CCVA儿童方面，MCB的有效性优于单独使用布地奈德。
